Tim Anderson
Stock Analyst at B of A Securities
(3.81)
# 609
Out of 4,829 analysts
33
Total ratings
63.16%
Success rate
6.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $575.15 | -4.89% | 2 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $171 → $159 | $154.40 | +2.98% | 5 | Apr 10, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $22 → $26 | $10.85 | +139.63% | 2 | Mar 27, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $104.00 | +21.15% | 2 | Mar 5, 2025 | |
| AMGN Amgen | Maintains: Underperform | $275 → $294 | $275.04 | +6.89% | 4 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $223 | $191.50 | +16.45% | 5 | Mar 4, 2025 | |
| MTSR Metsera | Initiates: Buy | $38 | $26.49 | +43.45% | 1 | Feb 25, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $25.75 | +32.04% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $80.75 | +38.70% | 4 | Feb 5, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $29 | $23.01 | +26.06% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $48.20 | +30.71% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $123.61 | +44.00% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $755.97 | +31.88% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $108.90 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $68.74 | - | 1 | Sep 22, 2017 |
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $575.15
Upside: -4.89%
Johnson & Johnson
Apr 10, 2025
Maintains: Neutral
Price Target: $171 → $159
Current: $154.40
Upside: +2.98%
Aardvark Therapeutics
Mar 27, 2025
Maintains: Buy
Price Target: $22 → $26
Current: $10.85
Upside: +139.63%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $104.00
Upside: +21.15%
Amgen
Mar 5, 2025
Maintains: Underperform
Price Target: $275 → $294
Current: $275.04
Upside: +6.89%
AbbVie
Mar 4, 2025
Maintains: Neutral
Price Target: $200 → $223
Current: $191.50
Upside: +16.45%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $38
Current: $26.49
Upside: +43.45%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $25.75
Upside: +32.04%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $80.75
Upside: +38.70%
Pfizer
Dec 10, 2024
Reinstates: Neutral
Price Target: $29
Current: $23.01
Upside: +26.06%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $48.20
Upside: +30.71%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $123.61
Upside: +44.00%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $755.97
Upside: +31.88%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $108.90
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $68.74
Upside: -